Cystatin C also may be employed as a trustworthy biological marker to predict AKI, particularly in assisting with early clinical identification of AKI, and AKI in hospitalized patients with COVID-19 is as high as 43% [13,14]. This evidence concerns the gene CST3 and acute kidney injury.